Evotec AG announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan.

Takeda Pharmaceutical Company Limited and PvP Biologics, Inc announced a global agreement for the development of KumaMax, a novel enzyme designed to break down the immune-reactive parts of gluten in the stomach, thereby avoiding the painful symptoms and damage done in the small intestine from accidental gluten ingestion.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Tretinoin.

Maverick Therapeutics Inc , an MPM Capital portfolio company, and Takeda Pharmaceutical Company Limited announced that they have entered a collaboration to develop Maverick’s T-cell engagement platform created specifically to improve the utility of T-cell redirection therapy for the treatment of cancer.

Marinus Pharmaceuticals Inc , a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders announced that the U.S. FDA has granted Orphan Drug Designation to its CNS-selective GABAA modulator, ganaxolone, for the treatment of Fragile X Syndrome (FXS).

IBM Watson Health and Pfizer Inc announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's research in immuno-oncology, an approach to cancer treatment that uses the body's immune system to help fight cancer.